Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc Studies
Authors:
- 20 June 2007
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 83 (1) , 153-159
Abstract
To assess the QTc prolongation by ritonavir (RTV) 100 mg and explore its potential use as CYP3A inhibitor in thorough QTc (TQT) studies. Randomized, crossover study of single-dose RTV 100 mg, placebo, and moxifloxacin (MFLX) 400 mg in 65 healthy subjects with serial triplicate electrocardiograms obtained for 12 h post-dose. Largest mean placebo-adjusted QTcF increase from baseline (90% confidence interval (CI)) for RTV 100 mg was noninferior to placebo (0.16 ms (-1.38, 1.69)). Study sensitivity was validated by detecting the largest mean placebo-adjusted QTcF increase from baseline (90% CI) for MFLX of 8.31 ms (6.44, 10.18). A single dose of RTV 100 mg does not cause QTc prolongation in healthy subjects. Based on the potent CYP3A4 inhibition, lack of QTc effect and better safety profile, RTV 100 mg could replace ketoconazole as the CYP3A4 inhibitor in TQT studies.Keywords
This publication has 33 references indexed in Scilit:
- Man Versus Machine: Is There an Optimal Method for QT Measurements in Thorough QT Studies?The Journal of Clinical Pharmacology, 2006
- Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 GuidelineThe Journal of Clinical Pharmacology, 2006
- Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperatureJournal of Pharmacological and Toxicological Methods, 2005
- Co‐administration of ketoconazole with H1‐antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effectsBritish Journal of Clinical Pharmacology, 2005
- Drugs, QT Interval Prolongation and ICH E14Drug Safety, 2005
- Regulatory advice on evaluation of the proarrhythmic potential of drugsJournal of Electrocardiology, 2004
- Drug‐Induced Torsades de Pointes and Implications for Drug DevelopmentJournal of Cardiovascular Electrophysiology, 2004
- Drug‐induced prolongation of the QT interval: why the regulatory concern?Fundamental & Clinical Pharmacology, 2002
- A review of the cardiac systemic side‐effects of antihistamines: ebastineClinical & Experimental Allergy, 1999
- Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequencesJAMA, 1993